Pancreatic cancer study failure cripples a Merrimack drug, forcing a coup de grâce and pipeline retreat
Eighteen months after Merrimack $MACK restructured, selling off its one marketed drug, switching out CEOs and circling the wagons around three key cancer drugs, the biotech has been forced to scuttle one of its priority drug programs.
MM-141 (istiratumab), has failed a Phase II pancreatic cancer study after investigators paired it with nab-paclitaxel and gemcitabine against the standard combo alone. There are no data in the statement, but the company said the drug flat failed on the primary and secondary endpoints, with nothing encouraging to report in the subgroup analysis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.